




PHARMACEUTICAL 2019

Cogent Biosciences Inc.
Rank 150 of 363





RealRate

PHARMACEUTICAL 2019

Cogent Biosciences Inc.
Rank 150 of 363



The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Cogent Biosciences Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 124%, being 87% points above the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 81,002 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 24,945 |
| Liabilities, Non-Current | 0 |
| Other Assets | 1,674 |
| Other Compr. Net Income | 4.0 |
| Other Expenses | 0 |
| Other Liabilities | 748 |
| Other Net Income | 1,473 |
| Other Revenues | 9,734 |
| Property and Equipment | 3,251 |
| Research and Development | 38,285 |
| Selling, General and Administrative Expense | 7,454 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 85,927 |
| Liabilities | 25,693 |
| Expenses | 45,739 |
| Revenues | 9,734 |
| Stockholders Equity | 60,234 |
| Net Income | -34,532 |
| Comprehensive Net Income | -34,530 |
| Economic Capital Ratio | 124% |